Novo Nordisk A/s

This study is testing whether a new weekly injection called NNC0487-0111 is safe and effective for helping people with obesity lose weight. About 600 adults will be randomly assigned to receive either the real injection or a placebo (a dummy injection with no medicine) for a set …

This study will monitor the safety and effectiveness of Rybelsus (oral semaglutide) in 600 Korean adults with type 2 diabetes during routine medical care. Participants will take Rybelsus as prescribed by their doctor and be followed for about 26 weeks. The research aims to collec…

This early study is testing a new drug called coramitug in people with ATTR-CM, a serious heart condition caused by abnormal protein clumps. Researchers want to see if coramitug can help remove these harmful protein deposits from the heart and prevent new ones from forming. They'…

This study is testing a weekly injection called CagriSema to see if it helps children and teenagers with type 2 diabetes better control their blood sugar and reduce their body weight. About 80 participants, aged 10 to 18, will be randomly assigned to receive either the real medic…

This study aims to see if two different injection devices for the weight loss medication CagriSema work the same way. About 1,400 adults with overweight or obesity will be randomly assigned to receive either the medication or a placebo for about one year. The main goal is to comp…

This study is testing a new weekly injection called NNC0487-0111 for people who have both excess body weight and knee osteoarthritis. The main goals are to see if the treatment helps participants lose weight and reduces their knee pain and stiffness. About 400 participants will b…

This early-stage study aims to see if combining two new experimental weight-loss drugs causes fewer stomach-related side effects, like nausea and vomiting, than taking just one of the drugs. About 100 adults with overweight or obesity will receive the drug combination in one part…

This study aims to see if a new weekly injection called NNC0487-0111 is safe and works better than the approved drug semaglutide for people with both excess weight and type 2 diabetes. About 1,000 adults will be randomly assigned to receive either the new drug or semaglutide, bot…

This study is testing a new weekly injection called NNC0662-0419 to see if it can help control blood sugar and body weight in people with type 2 diabetes. It will compare the new drug to a placebo (a dummy shot) and to an already approved diabetes medication, semaglutide. The goa…

This study aims to see how well an experimental medicine called CagriSema helps lower blood sugar in people with type 2 diabetes. Researchers will compare two different injection devices to deliver the same medicine. About 400 adults will participate for approximately 38 weeks to…

This study will monitor the safety and effectiveness of Ozempic (semaglutide) in 600 Korean adults with type 2 diabetes during their regular medical care. Participants will receive Ozempic as prescribed by their doctor, and researchers will track their health outcomes for about 6…

This study looks back at medical records to compare how well Ozempic protects against heart and kidney problems compared to other diabetes medications. Researchers will analyze data from 100,000 Chinese patients with type 2 diabetes who have taken these medications. The goal is t…